Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.alembicpharmaceuticals.com | |
Market Cap | 19,479.41 Cr. | |
Enterprise Value(EV) | 20,195.59 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 30.03 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 33.00 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.74 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 236.59 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 4.19 | Calculated using Price: 991.00 |
Dividend Yield | 0.81 | Period Ending 2023-03 |
No. of Shares Subscribed | 19.66 Cr. | 196,563,124 Shares |
FaceValue | 2 | |
About Alembic Pharmaceuticals Ltd. | ||
The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments. |
1 Day |
|
-0.73% |
1 Week |
|
+6.36% |
1 Month |
|
+3.43% |
3 Month |
|
+5.16% |
6 Month |
|
+30.48% |
1 Year |
|
+83.06% |
2 Year |
|
+29.44% |
5 Year |
|
+85.72% |
10 Year |
|
+223.51% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 36.24 | 58.02 | 23.25 | 20.42 | 24 | 26.97 | 26.91 | 10.11 | 7.12 | |
Return on Capital Employed (%) | 37.54 | 65.86 | 28.87 | 22.15 | 22.66 | 23.3 | 26.28 | 11.25 | 7.44 | |
Return on Assets (%) | 17.47 | 32.07 | 14.97 | 12.25 | 13.15 | 14.37 | 16.95 | 7.34 | 5.15 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 885 | 1,597 | 1,902 | 2,220 | 2,719 | 3,219 | 5,067 | 5,238 | 4,370 | 4,470 | |
Non Curr. Liab. | 72 | 84 | 94 | 576 | 570 | 1,047 | 361 | 162 | 52 | 52 | |
Curr. Liab. | 908 | 944 | 814 | 1,267 | 1,664 | 1,954 | 1,533 | 1,831 | 1,641 | 1,810 | |
Minority Int. | 0 | 0 | -1 | -29 | |||||||
Equity & Liab. | 1,865 | 2,626 | 2,811 | 4,064 | 4,952 | 6,192 | 6,961 | 7,230 | 6,064 | 6,332 | |
Non Curr. Assets | 750 | 917 | 1,317 | 2,116 | 2,820 | 3,526 | 4,057 | 4,255 | 3,150 | 3,197 | |
Curr. Assets | 1,115 | 1,708 | 1,494 | 1,948 | 2,132 | 2,665 | 2,904 | 2,975 | 2,914 | 3,134 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 1,865 | 2,626 | 2,811 | 4,064 | 4,952 | 6,192 | 6,961 | 7,230 | 6,064 | 6,332 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 2,056 | 3,166 | 3,135 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,118 | |
Other Income | 12 | 9 | 3 | 35 | 27 | 14 | 87 | 50 | 3 | 26 | |
Total Income | 2,068 | 3,175 | 3,137 | 3,166 | 3,962 | 4,620 | 5,481 | 5,356 | 5,656 | 6,144 | |
Total Expenditure | -1,661 | -2,161 | -2,520 | -2,516 | -3,079 | -3,392 | -3,913 | -4,432 | -4,945 | -5,233 | |
PBIDT | 407 | 1,014 | 617 | 650 | 883 | 1,228 | 1,568 | 925 | 711 | 911 | |
Interest | -4 | -5 | -5 | -3 | -18 | -27 | -16 | -18 | -50 | -60 | |
Depreciation | -44 | -72 | -83 | -105 | -115 | -157 | -183 | -287 | -275 | -277 | |
Taxation | -76 | -216 | -122 | -120 | -157 | -199 | -253 | -104 | -13 | 25 | |
Exceptional Items | -44 | ||||||||||
PAT | 283 | 720 | 407 | 421 | 593 | 801 | 1,115 | 521 | 342 | 599 | |
Minority Interest | 0 | 0 | 1 | 28 | |||||||
Share Associate | 0 | -4 | -8 | -9 | 0 | 32 | -9 | ||||
Other Related Items | |||||||||||
Consolidated Net Profit | 283 | 720 | 403 | 413 | 584 | 829 | 1,147 | 521 | 342 | 590 | |
Adjusted EPS | 15 | 38 | 21 | 22 | 31 | 44 | 58 | 27 | 17 | 30 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 240 | 172 | 948 | 329 | 312 | 812 | 449 | 1,463 | 552 | 724 | |
Cash Fr. Inv. | -81 | -256 | -307 | -486 | -884 | -756 | -732 | -839 | -372 | -448 | |
Cash Fr. Finan. | -151 | 87 | -224 | -129 | 503 | 59 | 155 | -597 | -217 | -262 | |
Net Change | 8 | 3 | 417 | -286 | -69 | 115 | -128 | 27 | -37 | 14 | |
Cash & Cash Eqvt | 24 | 27 | 439 | 153 | 84 | 199 | 72 | 98 | 61 | 75 |
Thu, 25 Apr 2024
Updates Alembic Pharmaceuticals Limited has informed the Exchange regarding 'Announcement under Regulation 30 of SEBI LODR Regulations, 2015'. |
Thu, 25 Apr 2024
Loss/Duplicate-Share Certificate-XBRL Alembic Pharmaceuticals Limited has informed the Exchange about Loss of share certificates |
Thu, 25 Apr 2024
Loss of Share Certificates Alembic Pharmaceuticals Limited has informed the Exchange about Loss of Share Certificates |
Thu, 25 Apr 2024 |
Higher Trade Quantity |
Closing Above Previous High |
Close Within 52 Week High Zone |
Closing Above Previous High for 2 Days |
Making Higher Highs for 2 Days |